Abstract: The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X): wherein Y?, X?, B?, R1?, R2?, R3?, R5?, R6?, R7?, and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The pyrazole derivatives of formula (I) or salts thereof modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also relates to the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease.

Abstract: Disclosed are phenyl-alkylene benzamides useful as orexin antagonists

Abstract: This invention relates to certain benzamide derivatives and their use as pharmaceuticals.

Abstract: A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate, or hydtrate thereof, processes for preparing said compounds and pharmaceutical compostions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Abstract: A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Abstract: A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Abstract: A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Abstract: A (+)or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Abstract: Compounds of formula (I), wherein R.sup.1 represents halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, NO.sub.2, --NR.sup.4 R.sup.5, R.sup.4 R.sup.5 NCO(CH.sub.2).sub.m --, R.sup.4 R.sup.5 NSO.sub.2 (CH.sub.2).sub.m --, R.sup.6 CONH(CH.sub.2)-.sub.m or R.sup.7 SO.sub.2 NH(CH.sub.2).sub.m --; R.sup.4 and R.sup.5 each independently hydrogen or C.sub.1-4 alkyl or NR?.sub.4 R.sup.5 represents a 5- to 7-membered heterocyclic ring, R.sup.6 represents hydrogen or C.sub.1-4 alkyl; R.sup.7 represents C.sub.1-4 alkyl; m is zero, 1 or 2; n is zero or 1 to 5; R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or --NR.sup.2 R.sup.3 represents a pyrrolidino, piperidino or hexahydroazepino ring, and A represents a bond, a C.sub.1-5 alkylene chain or a C.sub.3-5 alkenyle chain wherein the double bond is not adjacent the nitrogen atom; and salts thereof have affinity for the 5-HT.sub.1 -like receptor and are useful e.g. in the treatment of migraine.

Abstract: The invention provides the use of a compound of formula (I) ##STR1## wherein A, E, F, U, X, Y, Z, are as defined in the specification, or a pharmaceutically acceptable salt thereof, for the treatment of diarrhea predominant irritable bowel syndrome.